Rule 2.7, 3.10.3, 3.10.4, 3.10.5

### **Appendix 3B**

# New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/2012

Name of entity

THE GO2 PEOPLE LTD

 $\overline{ABN}$ 

45 616 199 896

We (the entity) give ASX the following information.

#### Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

1 \*Class of \*securities issued or to be issued

Performance Rights

Number of \*securities issued or to be issued (if known) or maximum number which may be issued

6,000,000

3 Principal terms of the +securities (eg, if options, exercise price and expiry date: if partly paid +securities, the amount outstanding and due dates for payment; if +convertible securities, the conversion and dates price conversion)

Expiry Date – 31 December 2020

Exercise price - nil

Vesting Conditions – holder to maintain employment with The GO2 People Ltd up to and until 1 July 2020

<sup>+</sup> See chapter 19 for defined terms.

4	Do the *securities rank equally in all respects from the date of allotment with an existing *class of quoted *securities?  If the additional securities do not	N/A
	<ul> <li>the additional securities do not rank equally, please state:</li> <li>the date from which they do</li> <li>the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment</li> <li>the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment</li> </ul>	
5	Issue price or consideration	Nil
6	Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)	Performance Rights Issued pursuant to Performance Rights Plan as employee retention incentives.
6a	Is the entity an *eligible entity that has obtained security holder approval under rule 7.1A?  If Yes, complete sections 6b – 6h <i>in relation to the *securities the subject of this Appendix 3B</i> , and comply with section 6i	No
6b	The date the security holder resolution under rule 7.1A was passed	N/A
6c	Number of *securities issued without security holder approval under rule 7.1	N/A
6d	Number of *securities issued with security holder approval under rule 7.1A	N/A

Appendix 3B Page 2 01/08/2012

<sup>+</sup> See chapter 19 for defined terms.

)	6e	Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	Nil	
	6f	Number of securities issued under an exception in rule 7.2	6,000,000	
	6g	If securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the issue date and both values. Include the source of the VWAP calculation.	N/A	
	6h	If securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	N/A	
	6i	Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements	Rule 7.1 – 17,694,687	
	7	Dates of entering *securities into uncertificated holdings or despatch of certificates	N/A	
			Number	Class
		•		

<sup>+</sup> See chapter 19 for defined terms.

#### Appendix 3B New issue announcement

8.	Number and *class of all *securities quoted on ASX (including the securities in section 2 if applicable)	117,964,583	Fully Paid Ordinary Shares
9.	Number and *class of all *securities not quoted on ASX ( <i>including</i> the securities in section 2 if applicable)	2,500,000	Options exercisable at \$0.225 each and expiring 21 June 2021
		5,000,000	Options exercisable at \$0.30 each and expiring 21 June 2021
		1,750,000	Options exercisable at \$0.30 each and expiring 17 December 2021
		7,500,000	Options exercisable at \$0.40 each and expiring 21 June 2021
		6,000,000	Performance rights exercisable for nil consideration, vesting 1 July 2020 and expiring 31 December 2020
10	Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)	N/A	
Part 2 - Bonus issue or pro rata issue			
11	Is security holder approval required?	N/A	
12	Is the issue renounceable or renounceable?	non- N/A	
13	Ratio in which the <sup>+</sup> securities will offered	be N/A	
14	<sup>+</sup> Class of <sup>+</sup> securities to which the orelates	offer N/A	
15	<sup>+</sup> Record date to determine entitlement	nts N/A	

Appendix 3B Page 4 01/08/2012

<sup>+</sup> See chapter 19 for defined terms.

16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?	N/A
17	Policy for deciding entitlements in relation to fractions	N/A
18	Names of countries in which the entity has *security holders who will not be sent new issue documents  Note: Security holders must be told how their entitlements are to be dealt with.  Cross reference: rule 7.7.	N/A
19	Closing date for receipt of acceptances or renunciations	N/A
20	Names of any underwriters	N/A
21	Amount of any underwriting fee or commission	N/A
22	Names of any brokers to the issue	N/A
23	Fee or commission payable to the broker to the issue	N/A
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of *security holders	N/A
25	If the issue is contingent on *security holders' approval, the date of the meeting	N/A
26	Date entitlement and acceptance form and prospectus or Product Disclosure Statement will be sent to persons entitled	N/A
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	N/A

<sup>+</sup> See chapter 19 for defined terms.

#### Appendix 3B New issue announcement

28		rights trading will begin (if acable)
29	Date appli	rights trading will end (if cable)
П		
30		do <sup>+</sup> security holders sell their lements <i>in full</i> through a broker?
31	their	do *security holders sell <i>part</i> of entitlements through a broker and of the balance?
	32	How do *security holders dispose of their entitlements (except by sale through a broker)?
	33	+Despatch date N/A
		<b>3 - Quotation of securities</b> ed only complete this section if you are applying for quotation of securities  Type of securities (tick one)
	(a)	Securities described in Part 1
	(b)	All other securities  Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities
	Entities that have ticked box 34(a)  Additional securities forming a new class of securities  Tick to indicate you are providing the information or documents	
	35	If the *securities are *equity securities, the names of the 20 largest holders of the additional *securities, and the number and percentage of additional *securities held by those holders
	36	If the *securities are *equity securities, a distribution schedule of the additional *securities setting out the number of holders in the categories 1 - 1,000

Appendix 3B Page 6 01/08/2012

<sup>+</sup> See chapter 19 for defined terms.

10,001 - 100,000 100,001 and over A copy of any trust deed for the additional \*securities 37 Entities that have ticked box 34(b) 38 Number of securities for which <sup>+</sup>quotation is sought 39 Class of +securities for which quotation is sought 40 Do the \*securities rank equally in all respects from the date of allotment with an existing \*class of quoted +securities? If the additional securities do not rank equally, please state: the date from which they do the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment 41 Reason for request for quotation Example: In the case of restricted securities, end of restriction period (if issued upon conversion of another security, clearly identify that other security) Number +Class 42 Number and +class of all +securities **ASX** quoted on (including the securities in clause 38)

<sup>+</sup> See chapter 19 for defined terms.

#### **Quotation agreement**

- <sup>+</sup>Quotation of our additional <sup>+</sup>securities is in ASX's absolute discretion. ASX may quote the <sup>+</sup>securities on any conditions it decides.
- We warrant the following to ASX.
  - The issue of the \*securities to be quoted complies with the law and is not for an illegal purpose.
  - There is no reason why those \*securities should not be granted \*quotation.
  - An offer of the +securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C (6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any \*securities to be quoted and that no-one has any right to return any \*securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the \*securities be quoted.
- If we are a trust, we warrant that no person has the right to return the 
  +securities to be quoted under section 1019B of the Corporations Act at 
  the time that we request that the +securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document not available now, will give it to ASX before 'quotation of the 'securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Date:

26 November

Sign here: 2019

(Company secretary)

Print name: Matthew Thomson

+ See chapter 19 for defined terms.

Appendix 3B Page 8 01/08/2012

## Appendix 3B – Annexure 1

## Calculation of placement capacity under rule 7.1 and rule 7.1A for †eligible entities

Introduced 01/08/12

#### Part 1

Rule 7.1 – Issues exceeding 15% of capital		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
Insert number of fully paid ordinary securities on issue 12 months before date of issue or agreement to issue	117,964,583	
Add the following:		
Number of fully paid ordinary securities issued in that 12 month period under an exception in rule 7.2	Nil	
Number of fully paid ordinary securities issued in that 12 month period with shareholder approval	Nil	
Number of partly paid ordinary securities that became fully paid in that 12 month period	Nil	
<ul> <li>Note:</li> <li>Include only ordinary securities here – other classes of equity securities cannot be added</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>		
<b>Subtract</b> the number of fully paid ordinary securities cancelled during that 12 month period	Nil	
"A"	117,964,583	

<sup>+</sup> See chapter 19 for defined terms.

"B"	0.15
	[Note: this value cannot be changed]
<b>Multiply</b> "A" by 0.15	17,694,687
Step 3: Calculate "C", the amount of that has already been used	of placement capacity under rule 7.1
Insert number of equity securities issued or agreed to be issued in that 12 month period not counting those issued:	Nil
• Under an exception in rule 7.2	
• Under rule 7.1A	
<ul> <li>With security holder approval under rule</li> <li>7.1 or rule 7.4</li> </ul>	
Note:  This applies to equity securities, unless specifically excluded – not just ordinary securities  Include here (if applicable ) the securities the subject of the Appendix 3B to which this form is annexed  It may be useful to set out issues of securities on different dates as separate line items	
"C"	Nil
Step 4: Subtract "C" from ["A" x "E capacity under rule 7.1	B"] to calculate remaining placemen
"A" x 0.15	17,694,687
Note: number must be same as shown in Step 2	
Subtract "C"	nil
Note: number must be same as shown in Step 3	
<i>Total</i> ["A" x 0.15] – "C"	17,694,687
	[Note: this is the remaining placement capacity under rule 7.1]

Appendix 3B Page 10 01/08/2012

<sup>+</sup> See chapter 19 for defined terms.

#### Part 2

Rule 7.1A – Additional placement capacity for eligible entities		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
"A"	N/A	
Note: number must be same as shown in Step 1 of Part 1		
Step 2: Calculate 10% of "A"		
"D"	0.10	
	Note: this value cannot be changed	
Multiply "A" by 0.10	N/A	
Step 3: Calculate "E", the amount of placement capacity under rule 7.1A that has already been used		
<b>Insert</b> number of equity securities issued or agreed to be issued in that 12 month period under rule 7.1A	Nil	
<ul> <li>Notes:</li> <li>This applies to equity securities – not just ordinary securities</li> <li>Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed</li> <li>Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>		
"E"	Nil	

<sup>+</sup> See chapter 19 for defined terms.

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A		
"A" x 0.10	N/A	
Note: number must be same as shown in Step 2		
Subtract "E"	Nil	
Note: number must be same as shown in Step 3		
<i>Total</i> ["A" x 0.10] – "E"	N/A	
	Note: this is the remaining placement capacity under rule 7.1A	

Appendix 3B Page 12 01/08/2012

<sup>+</sup> See chapter 19 for defined terms.